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Abstract
Introduction: Important clues in the recognition of individuals with dystrophin gene mutations are
illuminated in this case report. In particular, this report seeks to broaden the perspective of early
signs and symptoms of a potentially life-limiting genetic disorder. This group of disorders is generally
considered to be a pediatric muscular dystrophy when in actual fact, this case report may represent a
spectrum of subclinically affected adults.
Case presentation: We present the diagnostic saga of a 34-year-old Caucasian man who had two
liver biopsies for elevated liver enzymes and 16 years later presented with a cardiac arrhythmia
amidst an emergent appendectomy which finally led to his specific genetic diagnosis.
Conclusions: This genetic disorder can affect more than one organ, and in our patient affected both
skeletal and cardiac muscle. Furthermore, liver function tests when elevated may erroneously
implicate a liver disorder when they actually reflect cardiac and skeletal muscle origin. Presented here
is a patient with Becker’s muscular dystrophy and cardiomyopathy.
Introduction
Dystrophinopathies are X-linked recessive disorders caused
by loss of functionmutations affecting the dystrophin gene
[1]. The dystrophin gene consists of 79 exons which encode
a huge 427 kDa membrane-associated protein found in
some neurons and all muscle cells [2]. As large interna-
tional genetic databases are maturing, it is becoming clear
that dystrophinopathies present a spectrum of phenotypes
and comorbidities. Becker’s muscular dystrophy (BMD)
and Duchenne’s muscular dystrophy (DMD) are estimated
to occur in 1:12,000 and 1:3500 male births, respectively.
Intragenic deletions are the 3500most commonmutations
leading to BMDorDMD. Patients with BMDexhibitmilder
progressive muscular dystrophy with ambulation main-
tained into the teenage and adult years [3]. On the other
hand, patients with DMD tend to lose independent
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ambulation by 15 years of age and are life-limited by the
end of the second decade usually due to cardiorespiratory
compromise.
We present the case of a patient diagnosed with BMD in
the middle of his fourth decade of life. Cardiac and skeletal
muscle symptoms were absent until an emergent appen-
dectomy when he was found to have a paradoxical
arrhythmia. After a prolonged evaluation, our patient was
shown to have a 2 bp out-of-frame deletion in exon 2 of his
dystrophin gene, where the total gene has 79 exons.
Case presentation
The patient had been a lifelong participant in sports,
including baseball, soccer, basketball, cycling, volleyball,
racquetball, running, and skiing, but noted occasional
cramps while playing soccer that improved with rest. He
could never do pull-ups nor run the mile in standard peer-
group times. He was often told as a child and adult that he
had large powerful-looking calves. He excelled academi-
cally, and attended graduate school in engineering. He
currently runs his own internet business. The family
history was non-contributory.
In late September 2005, this 34-year-old Caucasian man
entered the emergency department with right lower
quadrant pain confirmed to be acute appendicitis and he
underwent an emergent appendectomy. During the
operation, he developed a very irregular heartbeat. He
was referred to a local cardiologist who diagnosed him
with asymptomatic idiopathic dilated cardiomyopathy,
NYHA class I to II. An electrocardiogram (EKG) showed
his left ventricular ejection fraction to be 30%, where the
normal range is 55-75%.
Priormedical and surgical history included a longhistory of
elevated liver enzymes, having aspartate aminotransferase
(AST) levels of 79-102 IU/L (normal 12-31 IU/L) and
alanine aminotransferase (ALT) levels of 120-180 IU/L
(normal 1-21 IU/L) which were incidentally found in
screening tests before starting acne medication in 1990. A
liver biopsy was performed at that time, and a second liver
biopsy was performed five years later. Both biopsies found
no pathologic hepatic abnormalities. In 1997, he presented
with palpitations and after an EKG, was told that he had a
left bundle branch block that was not investigated further.
An X-ray of the patient’s chest in August 1997 showed
cardiac size to be on the upper limits of normal. From
October 2005 to December 2006, a local cardiologist
repeated several studies including six EKGs, three echocar-
diograms, a nuclear treadmill stress test, two treadmill stress
tests, and a cardiac catheterization, without any further
diagnostic clarity for an underlying etiology. He was told
that he likely had an idiopathic cardiomyopathy, possibly
post-viral. He denied ever being ill to such an extent. His
physical exam was thought to be normal otherwise.
In November 2006, he independently sought third and
fourth opinions with cardiologists at two leading tertiary
academic medical centers. At one center, he was tested and
found to have an elevated serum creatine kinase (CPK)
of 1011 IU/L (normal 0-250 IU/L). His physical exam
showed mild symmetrical proximal muscle weakness and
minimal weakness of the hamstrings, depressed stretch
reflexes at his knees with downgoing toes and a significant
calf pseudo-hypertrophy.
Echocardiography in November 2006 revealed severe left
ventricle (LV) enlargement and an LV ejection fraction of
25-30% (normal = 55-75%). At that time, a blood DNA
genetic test was ordered which revealed a presumed
disease-causing mutation in his dystrophin gene. The
DNA sequencing analysis revealed a 2 base pair deletion of
guanidine and adenine in nucleotide positions 40 and 41
of exon 2 (total of 79 exons in the dystrophin gene).
Dystrophin carrier testing in his mother was negative for
this specific mutation, suggesting that a spontaneous
mutation had occurred.
Skeletal and cardiac muscle biopsies were performed. A
left vastus lateralis muscle (Figure 1) biopsy revealed
chronic myopathy with fiber splitting, increased internal
nuclei (up to 40%), and isolated necrotic and regenerating
fibers. Immunohistochemical staining specific for three
epitopes of dystrophin showed that the N-terminus was
normal but the rod domain and C-terminus showed
patchy staining unlike the control sections. Western blot of
skeletal muscle showed that dystrophin was approxi-
mately normal size (≈427 kDa) and 33.7% of normal
abundance compared to controls (Figure 2).
A cardiac muscle biopsy revealed no pathologic findings to
support myocarditis, but mild fibrosis and increased
variability in cardiac myocyte diameter and the nuclear
morphology were consistent with a cardiomyopathy.
Immunoperoxidase staining following antigen retrieval
with proteinase K was performed on his wax-embedded
cardiac biopsy. Dystrophin immunostaining with both the
rod domain and amino-terminus antibodies using dysA
and dysB, respectively, (Novocastra) were both markedly
reduced (Figure 3) compared to control. Alpha-dystrogly-
can had a similar immunolabeling using the glycoepitope-
specific antibody IIH6 (Upstate) supporting patient tissue
integrity. No frozen cardiac tissue was available to perform
a Western blot.
An implantable cardioverter defibrillator (ICD) was
placed in July 2007 due to concerns of a paroxysmal
life-threatening arrhythmia. At the time of writing, the
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patient is scheduled for an arrhythmia ablation procedure to
remove an abnormal conduction pathway.Hehas been told
that, in the future, if his heart problemcontinues toprogress,
he may need to be considered for cardiac transplantation.
Discussion
This case report describes a healthymanwho presentedwith
a life-threatening arrhythmia on the operating table andwas
subsequently diagnosed with BMD, based on the clinical
features, the genetic testing and the skeletal muscle analysis.
The patient had elevated liver enzymes 16 years before his
arrhythmia. Liver disease was assumed so the patient
underwent two liver biopsies which were both unreveal-
ing. Skeletal and cardiac muscle disease can be found with
elevations in soluble metabolic enzymes, for example, AST
and ALT. Thus, blood test screening for both serum CPK
and gamma glutamyl-transferase (GGT) should be con-
sidered to distinguish liver from muscle abnormalities.
Cardiac abnormalities are common in patients with BMD
and may be the presenting symptom. In fact, cardiac
complications are a more frequent cause of death in
patients with BMD than in patients with DMD [4].
Angelini et al. found that 54% of electrocardiographic
and 65% of echocardiographic data were abnormal for
those patients with muscular dystrophy given extensive
cardiac evaluation [5]. These patients experience LV
dysfunction and could require a ventricular assist device
or heart transplantation. Our patient required an ICD, and
will have arrhythmia ablation surgery. Doing et al.
reported that a trial of beta blockers and angiotensin
converting enzyme inhibitors (ACEIs) can be a successful
intervention, delaying or omitting the need for heart
transplantation [6].
In 1996, Saito et al. showed that patients with BMD had
poorer LV systolic function, as measured by pre-ejection
time period/ejection time (PEP/ET); larger LV end diastolic
dimension (LVDd), and a larger mitral valve annular size
at end diastole compared to patients with DMD and with
healthy controls [4]. They also showed that mitral
regurgitation was present significantly more often in
patients with BMD with cardiac failure compared to
patients with BMD without cardiac failure.
Our patient showed a clinical picture consistent with
BMD, despite a frame-shift mutation. As a further
paradox, the frameshift DNA hypothesis predicts the
DMD phenotype with out-of-frame mutations and the
BMD phenotype is predicted for mutations that keep
the reading frame intact. With this case in mind,
diagnostic laboratories and physicians must be cautious
not to offer overstated genetic results without validated
population clinical data plus immunohistochemical data
or a protein study.
Why does this specific dystrophin mutation in our patient
affect his cardiac function more than his skeletal muscle
which is mildly weak? In 1996, Angelini et al. conducted a
large-scale survey of mild dystrophinopathies and found a
sizable group of patients lacking severe muscle wasting but
presenting with severe cardiac conditions [5]. They suggest
that muscle up-regulates the expression of isoforms of
dystrophin but the heart does not, an idea also presented
by Milasin et al. [2].
Figure 2. Western blot of human skeletal muscle probed
with 427 kDa monoclonal anti-dystrophin MANDRA 1 against
the C-domain of the dystrophin protein (Sigma, St Louis, MO,
USA) and reprobed with 116 kDa monoclonal anti-vinculin
hVIN-1 (Sigma). Lane 1 is control skeletal muscle; Lane 2 is a
biopsy sample from the patient of interest, at 33% of control
levels of dystrophin protein [12]; Lane 3 is a biopsy sample
from a patient with Duchenne’s muscular dystrophy;
40 μg skeletal muscle per lane.
Figure 1. Patient and control skeletal muscle biopsies:
hematoxylin and eosin and anti-dystrophin immunoperoxidase
staining is diffusely attenuated for three epitopes of dystrophin
protein (N-terminus; rod domain; C-terminus, 20x).
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In 2006, Aartsma-Rus et al. showed that only 2% of all
patients have an out-of-frame deletion or duplication
associated with a BMD phenotype [3]. In 2008, Kesari et al.
published data showing 30% reading-frame exceptions in
patients with DMD, especially with deletions at the 5’ end
of the gene [7]. In 1996, Angelini et al. showed that a
deletion at the 5’ end of the gene is usually associated with
a rapid disease course; our patient contradicted this
observation [5]. Mutations at the 5’ end of the DMD
gene can result in dystrophinopathy with substantial
cardiac involvement [2]. Patients with dystrophin-defi-
cient X-linked cardiomyopathy have dystrophin deletions
or alternative splicing mutations that affect the 5’ end of
the gene, specifically the muscle promoter and muscle
specific exon 1. In every case, the cardiac muscle was
dystrophin-deficient while the skeletal muscle dystrophin
level was normal. They also found that the heart muscle
dystrophin transcripts in their patient with the 5’ deletion
were comparable to patients with XLDCM (X-linked
dilated cardiomyopathy) [2].
Conclusion
This patient was a diagnostic challenge for physicians
including pediatricians, internists, family practitioners,
neurologists, gastroenterologists and cardiologists. In
1997, Muntoni et al. reported two patients who presented
with idiopathic dilated cardiomyopathy (IDCM) later
proven to be caused by dystrophin gene deletions [8].
Myopathic symptoms may be delayed and mild in BMD,
even when there is severe cardiomyopathy. Cardiac
symptoms can appear in any individual with dystrophin
gene mutations and can be progressive. Early identifica-
tion may enable earlier prophylactic treatment with
afterload reducing medications and possibly even corti-
costeroids which have been favorable in boys with DMD
[9]. It took three cardiac specialists from leading academic
cardiac hospitals to eventually clarify our patient’s
diagnosis from IDCM to cardiac dystrophinopathy with
BMD.
It is clear that cardiac involvement should be anticipated
in patients with BMD and will be progressive over time. In
a large study of 68 patients with BMD by Nigro et al. in
1995, it was found that every patient over 30 years of age
had cardiac involvement [10]. The rate of progression is
unpredictable and a large percentage of patients will be
affected with a disabling and potentially deadly dilated
cardiomyopathy [11]. Mutations at the 5’ end of the DMD
gene pose a great threat combining mild skeletal muscle
symptoms with severe cardiac involvement. Hopefully,
this case report will help raise awareness of dystrophino-
pathy disorders when abnormalities of the liver screening
tests, cardiomyopathy and mild skeletal muscle weakness
are discovered.
Patient’s perspective
There are many others with subclinical BMD symptoms
that go undiscovered until it is too late. Simple and
inexpensive CPK blood work screening should be pursued
in all infants/children, to find these conditions early.
Persons with elevated liver enzymes, heart conditions
such as cardiomyopathy, left bundle branch issues, and
idiopathic causes should also be screened to avoid
dangerous and unnecessary tests and procedures. Basic
medication safety screening also needs to be increased, to
protect patients and families frommedications/substances
that cause irreparable damage and con-artists who prey on
their optimism and wallets. Avoiding detrimental effects
and ineffective medications is the easiest, cheapest, and
safest way to stabilize the quality-of-life of these patients.
A clearinghouse of these data needs to be created so that
supplements and medicines, which have been proven to
be safe, effective, and helpful for patients with BMD with
heart conditions, are easily known to all doctors and
especially patients.
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